At a glance
ClinicalIndex Comparison RecordN/ACompleted· 103,101 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Engel 2: REal-life aNticoaGulants Comparative bEnefit-risk in Nonvalvular Atrial fibrilLation (NVAF) in France
In Brief
An observational study for Atrial Fibrillation. Completed, enrolled 103,101 participants across 1 site.
Detailed Summary
The study is an analysis using the French national health insurance database, six months after the beginning of NOAC launch in the NVAF indication. The aim is to compare the one-year, two-year and three-year benefit-risk (major bleeding, arterial thrombotic events, myocardial infarction (MI), death) between patients starting a NOAC and patients starting a VKA for NVAF in 2013
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsAtrial Fibrillation
CountriesFrance
Collaborators--
Timeline
N/ACompletedFinished
20162017201820192020202120222023202420252026
Enrollment StartMar 2016
Primary CompletionMar 2016
Study CompletionApr 2016
First PostedMay 2016
TodayJul 2026
First PostedMay 27, 2016
Enrollment StartMar 1, 2016
Primary CompletionMar 4, 2016
Study CompletionApr 5, 2016
TodayJul 2, 2026
Enrollment to primary: 3 daysPosted 10.1 years ago